Aldolase a coordinates macropinocytic nutrient scavenging and lysosomal degradation in lung cancer by interacting with V-ATPase Authors: Daehoon Kim, Seokmin Jeong, Seunghyeong Lee, Jonghwa Jin, Jae Won Yun, Jaebon Lee, Jun-Kyu Byun, Yeon-Kyung Choi, Keun-Gyu Park Published: 2025 ABSTRACT AbstractBackgroundOncogenic KRAS mutations in cancer cells drive macropinocytosis, a pathway that scavenges extracellular proteins to obtain nutrients under metabolic stress. Lysosomal degradation is essential for processing these proteins, but the precise molecular link between macropinocytic uptake and lysosomal processing remains largely unclear. Aldolase A (ALDOA), a glycolytic enzyme, has diverse non-canonical functions. While interactions between ALDOA and Vacuolar-type H⁺-ATPase (V-ATPase) subunits have been suggested, their functional role in lysosomal degradation of macropinocytosed cargo remains undefined.MethodsWe investigated the role of ALDOA using integrated approaches, including The Cancer Genome Atlas data analysis and in vitro assays of lung adenocarcinoma cell lines to evaluate macropinocytosis, lysosomal degradation, lysosomal pH, and interactions with V-ATPase. We also assessed mTORC1 signaling and cell proliferation under nutrient-deprived and anchorage-independent conditions. In vivo relevance was tested in xenograft tumor models.ResultsHigh expression of ALDOA correlated with a poor prognosis for patients with KRAS-mutant lung adenocarcinoma. Functionally, ALDOA selectively regulated lysosomal degradation of macropinocytosed proteins without affecting their uptake. Mechanistically, ALDOA interacted physically with V-ATPase subunits to increase lysosomal acidification, uncovering a novel, non-enzymatic role that is independent of its glycolytic function. This interaction was essential for efficient nutrient utilization, sustained mTORC1 activity, and cell proliferation under metabolic and mechanical stress. In vivo, depletion of ALDOA inhibited macropinocytosis-dependent tumor growth, phenocopying treatment with 5-(N-Ethyl-N-isopropyl) amiloride.ConclusionOur study identifies a novel, non-enzymatic function of ALDOA as a critical regulator of lysosomal degradation of macropinocytosed proteins via interaction with V-ATPase. This mechanism is essential for metabolic adaptation and growth of KRAS-mutant tumors under stress conditions. Targeting ALDOA offers a promising therapeutic strategy for cancers that rely on extracellular nutrient scavenging.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12964-025-02591-4.Keywords: Aldolase A, Macropinocytoosis, Lysosomal degradation, V-ATPase Introduction Cancer cells are frequently exposed to metabolic stress, which includes nutrient deprivation and detachment from the extracellular matrix; such conditions are a severe challenge to their survival and proliferative capacity [1, 2]. To adapt to such adversities, many tumors, particularly those harboring activating KRAS mutations, upregulate macropinocytosis, a specialized form of bulk endocytosis that enables internalization of extracellular proteins for use as alternative nutrient sources [3, 4]. Although the upstream regulatory mechanisms governing macropinocytosis are becoming clearer [5–7], the precise molecular mechanisms that functionally link macropinocytic uptake to subsequent lysosomal degradation and finely regulate this process remain poorly understood. Aldolase A (ALDOA) is a glycolytic enzyme best known for catalyzing cleavage of fructose-1,6-bisphosphate into glyceraldehyde-3-phosphate and dihydroxyacetone phosphate, an essential step in glycolysis often associated with cancer progression [8]; however, beyond its canonical metabolic role, ALDOA is a multifunctional protein with diverse non-glycolytic, or "moonlighting," activities. Recent studies suggest that ALDOA regulates mRNA translation, protein biosynthesis, and interactions with cytoskeletal structures and organelles [9, 10]. These observations position ALDOA as a versatile protein, with broad implications for cellular homeostasis and stress adaptation. Prior observations suggest among these emerging functions, ALDOA may interact with subunits of the vacuolar-type H⁺-ATPase (V-ATPase), which is critical for lysosomal acidification and proteolytic activity [11, 12]. Following macropinocytic uptake, extracellular proteins are delivered to lysosomes, where their degradation depends on the acidic environment maintained by V-ATPase activity [13, 14]. This connection between a metabolic enzyme and a structural regulator of lysosomal function raises the intriguing possibility that ALDOA may influence lysosomal homeostasis through non-canonical interactions. Yet, despite these insights, the functional relevance of the association between ALDOA and V-ATPase, particularly in the context of macropinocytosed cargo processing, remains undefined. In this study, we identify a novel, non-enzymatic role of ALDOA that facilitates degradation of lysosomal proteins independent of its glycolytic function. We show that ALDOA interacts physically with components of the V-ATPase complex and promotes lysosomal acidification. These findings reveal a previously unrecognized mechanism by which ALDOA supports nutrient acquisition under metabolic stress, and highlight its potential as a therapeutic target in macropinocytosis-reliant lung cancers, especially those driven by oncogenic KRAS. Materials and methods Cell culture and chemical treatment Human lung cancer cell lines A549, H358, H1437, and H522 were cultured in RPMI 1640 medium containing 10% fetal bovine serum and 1% penicillin/streptomycin. For anchorage-independent culture, culture dishes were coated with poly 2-hydroxyethyl methacrylate (poly-HEMA; Sigma, St. Louis, MO, USA) to prevent cell attachment. Poly-HEMA was dissolved at 20 mg/mL in 95% ethanol by incubating at 65℃ with continuous rotation until fully solubilized. Then, 60-mm culture dishes were coated with 1.3 mL of the poly-HEMA solution, dried in a 37℃ dry-oven, and stored at room temperature until use. A549 cells were pretreated for 2 h with a pharmacological inhibitor of micropinocytosis (EIPA; 5-(N-Ethyl-N-isopropyl)amiloride, 30 μM; Sigma). This treatment was maintained during the subsequent incubation with 3% BSA (Sigma). Western blot analysis Proteins in cell lysates were separated in Tris–Glycine gels and then transferred to Polyvinylidene difluoride (PVDF) membranes (Millipore Corporation, Bedford, MA, USA). After blocking with 5% skimmed milk, the membranes were incubated with antibodies specific for the following proteins: ALDOA, LAMP1, SLC38A2, SLC7A5 (Santa Cruz Biotechnology, Santacruz, CA, USA), phospho-S6K (T389), S6K, phospho-ULK1 (S757), ULK1, phospho-4EBP1 (S65), 4EBP1, COX4, GAPDH, CANX, GM130, FLAG, ATP6V1B2, SLC1A5, SLC38A1, SLC3A2 (Cell signaling, Danvers, MA, USA), ATP6V0A2 (Abclonal, Woburn, MA, USA), FITC (Invitrogen, Waltham, MA, USA), or β-ACTIN (Sigma). Following washes in TBST, the proteins on the membranes were visualized using a goat anti-IgG secondary antibody (GeneTex, Irvine, CA, USA). In vitro assays to measure macropinocytosis and protein degradation To conduct the in vitro micropinocytosis & lysosomal proteolysis assay, cancer cells were starved for 12 h in serum-free medium and then incubated with either TMR-dextran (70 kDa, 1 mg/mL; Thermo Fisher Scientific) for 1.5 h or DQ-BSA (10 μg/mL) for 4 h at 37 °C. After incubation, cells were washed three times with Phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde. Nuclei were counterstained using DAPI-containing mounting medium (Vector Laboratories, Burlingame, CA, USA). Confocal imaging was performed using an Olympus IX81 (Olympus, Tokyo, Japan) inverted microscope equipped with an FV1000 (Olympus) confocal laser scanning unit. DAPI was excited by the 405 nm laser, DQ-BSA (green) by the 473 nm laser, and TMR-dextran (red) by the 559 nm laser. Images were acquired as single optical sections in the DAPI focal plane. As described previously [15, 16], the amount of DQ-BSA or TMR-dextran within individual cells was measured using ImageJ (Fiji ver. 1.54 m). Background fluorescence, based on regions of interest (ROIs) drawn outside the cell area, were subtracted, and identical threshold settings were applied across all images. The mean fluorescence intensity, or number of puncta per cell, was calculated and normalized to control samples. For lysosomal inhibition, cells were pretreated for 1 h with bafilomycin A1 (100 nM; Sigma) before incubation with DQ-BSA. To assess degradation of macropinocytosed proteins, cells were first serum-starved for 12 h and then incubated for 4 h with FITC-BSA (1 mg/mL; Invitrogen). Transfection of siRNA and expression vectors For gene silencing, cells were transfected with scramble siRNA, siALDOA, or siPFKM (Bioneer, Co., Seoul, South Korea) using Lipofectamine™ RNAiMAX transfection reagent (Invitrogen). Reverse transfection was performed following the instructions of the manufacturer: siRNA–RNAiMAX complexes were prepared prior to cell seeding and added simultaneously with the cells. For three-dimensional (3D) culture, cells were reverse-transfected with siRNA on poly-HEMA–coated dishes at the time of seeding and maintained for 48 h. To suppress endogenous ALDOA while allowing subsequent expression of exogenous ALDOA, cells were first subjected to reverse transfection with an ALDOA-targeting siRNA (Bioneer) directed against the 3′-untranslated region (3′-UTR) of ALDOA using RNAiMAX for 24 h. The siRNA sequences were as follows: sense, 5′-UGA UGG ACU UAG CAU UCA C = tt(1-AA)−3′; antisense, 5′-GUG AAU GCU AAG UCC AUC A = tt(1-AS)−3′. Following siRNA treatment, cells were transfected with ALDOA expression vectors for an additional 48 h. For exogenous expression, cells were transfected with 0.5 μg of plasmids encoding Control (ID: VB010000-9389rbj), EF1A/hALDOA-T2A-FLAG (ID: VB231227-1172xjy), or EF1A/hALDOA(D34S)-T2A-FLAG (ID: VB231227-1175xdn) (VectorBuilder, San Jose, CA, USA) using Lipofectamine 3000 with the P3000 reagent (Invitrogen). These vectors contain only the ALDOA coding sequence and lack the ALDOA 3′-UTR, thereby preventing interference from the UTR-targeting siRNA. Quantitative RT-PCR Total RNA was isolated using QIAzol™ Lysis Reagent (Qiagen, Hilden, Germany), and cDNA was synthesized using the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). Gene expression analysis was performed using QuantStudio 5 (Applied Biosystems, Foster City, CA, USA) with SYBR Green PCR Master Mix (Applied Biosystems). Gene expression levels were normalized to the corresponding levels of human 36B4. The sequences of the primers used are as follows: 36B4 forward, CCACGCTGCTGAACATGCT, and reverse, TCGAACACCTGCTGGATGAC; PFKM forward, GGCACGGTGATTGGAAGTG, and reverse, TCGGAGTCGTCCTTCTCGTT. Immunofluorescence analysis Cells were incubated for 1 h with Lysotracker™ DND-99 (50 nM; Invitrogen) and then fixed for 20 min at room temperature in 4% paraformaldehyde. Samples were permeabilized for 15 min at room temperature with permeabilization buffer (0.1% Tween 20 and 0.01% TritonX-100 in PBS). After blocking for 1 h with 2% BSA, the samples were incubated overnight at 4 °C with anti-ALDOA (Proteintech, Rosemont, IL, USA), anti-ATP6V1B2 (Abcam, Cambridge, UK), or anti-LAMP1 (Santa Cruz). Following washing, the samples were incubated for 1 h at room temperature with Alexa Fluor® 488- or Fluor® 568- conjugated secondary antibodies (Invitrogen). For tumor tissue staining, deparaffinized samples were incubated with anti-ALDOA (Proteintech) and anti-LAMP1 (Santa Cruz) or anti-ALDOA (Santa Cruz) and anti-α-smooth muscle actin (α-SMA) (Cell Signaling). Nuclei were counterstained using a DAPI-containing mounting medium (Vector Laboratories). Co-localization analysis was performed using ImageJ (Fiji ver. 1.54 m) with the JACoP plugin (ver. 2.1.4) following a previously described method [17]. Specifically, ROIs were drawn to include only the cell area of interest, excluding the nucleus and background. Image A was assigned to ALDOA or ATP6V1B2 (green), and Image B to LAMP1 (red). Manders’ coefficients were calculated with Costes automatic thresholds applied, and the tM1 values (representing the fraction of the A signal overlapping with the B signal) were used for quantitative analysis. Lysosome isolation Lysosomes were isolated using a lysosome isolation kit (Abcam). Briefly, cells were resuspended in ice-cold isolation buffer and then disrupted with a glass Dounce homogenizer. After centrifugation at 500 × g for 10 min at 4 °C, the supernatant was collected and applied to a discontinuous density gradient. Lysosomal fractions were obtained by ultracentrifugation at 145,000 × g for 2 h at 4 °C. Immunoprecipitation To immunoprecipitate ALDOA, A549 cells were cultured to 80% confluency in four 100-mm dishes. Cells were then lysed with 1 mL of ice-cold Octyl-β-D-glucoside buffer (50 mM Tris–HCl pH 8.0, 50 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2% octyl-β-D-glucoside (Merck, Darmstadt, Germany), 5 mM β-mercaptoethanol, and protease inhibitor cocktail) and the lysates incubated with either a mouse IgG1 isotype control antibody (Cell Signaling) or an anti-ALDOA antibody (Santa Cruz) for 1 h at 4 °C on a rotator. This was followed by overnight incubation at 4 °C with Protein A/G agarose beads (Santa Cruz). After washing, the immunoprecipitates were eluted by boiling in LDS sample buffer (Thermo Fisher Scientific) at 70 °C for 10 min. Lysosomal pH assay Lysosomal pH was measured using the Lysosomal Acidic pH Detection Kit-Green/Red (Dojindo, Kumamoto, Japan). Briefly, after serum starvation, cells were washed with Hanks' Balanced Salt Solution (HBSS) and incubated for 30 min with LysoPrime Green in HBSS. After washing, cells were incubated for 30 min with pHLy Red, followed by washing with HBSS and staining of nuclei with NucBlue™ Live ReadyProbes™ Reagent (Invitrogen). Use of shell analysis to measure lysosome position A “shell analysis” of Z-stack confocal images acquired using a Leica TCS SP5 laser scanning confocal microscope (Leica Microsystems, Wetzlar, Germany) was performed to assess the distribution of lysosomes. Z-stack imaging was performed with an average of 18 optical sections per cell, collected at a wavelength of 405 nm excitation/420–480 nm emission (DAPI) or 561 nm excitation/570–620 nm emission (Alexa Fluor 568). Transmitted light images were recorded simultaneously to visualize cell morphology. Maximum intensity projection images were generated for subsequent analysis. Shell analysis was performed using ImageJ (Fiji ver. 1.54 m), as described previously [18]. ROIs were defined from the nuclear boundary to the cell periphery, and divided evenly into five concentric shells, each corresponding to one-fifth of the mean distance from the plasma membrane to the cell center. Within each shell, the LAMP1-positive area was measured and expressed as the percentage of the total LAMP1 signal per cell. For positional analysis, shells #1–3 were designated as the peripheral region, whereas shells #4–5 were designated as the perinuclear region. Cell proliferation Cells were transfected for 48 h with either siRNAs or expression plasmids. Following transfection, cells were subjected to serum depletion for 12 h, and then cultured in leucine-free medium contained 10% dialyzed FBS, with or without 3% BSA (Sigma). After 24 h, cells were detached using trypsin–EDTA (Thermo Fisher Scientific, Waltham, MA, USA) and counted using a hemocytometer. Cell viability Cell viability was measured by Trypan Blue exclusion. Briefly, cells were trypsinized and mixed 1:1 with 0.4% Trypan Blue solution (Thermo Fisher Scientific). Viable (unstained) and non-viable (blue-stained) cells were counted, and viability was expressed as the percentage of viable cells among total cells. Generation of a stable cell line Lentiviral vectors hCas9/Puro-U6/Scramble[gRNA] and hCas9/Puro-U6/hALDOA[gRNA] (VectorBuilder) were used to generate ALDOA-knockout A549 cells. Lentiviruses were produced in HEK293T cells using Lenti-X™ Packaging Single Shots (Takara, Kusatsu, Shiga, Japan). The resulting viral supernatants were applied to A549 cells in the presence of polybrene (Sigma). Transduced cells were cultured for 14 days in medium containing puromycin (Sigma) with serial passaging. After the selection period, cells exhibiting complete loss of ALDOA protein were identified by immunoblotting, and expanded as a stable population. Animal model A subcutaneous xenograft model was established to evaluate tumor growth. Control A549 or ALDOA-knockout A549 cells (5 × 106) were suspended in 100 μL of PBS and injected subcutaneously into the flanks of 5-week-old male BALB/c nude mice. Once tumors reached approximately a volume of 100 mm3, EIPA (30 μM in 50 μL PBS) was administered daily via intra-tumoral injection until the mice were euthanized at the experimental endpoint. Tumor size was measured using calipers, and volume was calculated using the formula: length × width2 × 0.5 (mm3). All animal experiments were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee of Kyungpook National University (approval number: 2525–0207). DQ-BSA assay in xenograft tumors Based on previous studies labeling macropinosomes in xenograft tumors [16], a lysosomal proteolysis assay was performed in mouse tumors using DQ-BSA (Thermo Fisher Scientific). Briefly, mice were anesthetized and tumors injected directly with 100 μL DQ-BSA (2 mg/mL) using a 28G insulin syringe. After 4 h, mice were euthanized in accordance with institutional guidelines. Tumors were excised immediately and embedded in Optimal Cutting Temperature (OCT) compound in cryomolds, before being snap-frozen. Once fully frozen, the OCT-embedded tumors were sectioned using a cryostat, and the cryosections were mounted onto glass slides. Sections were washed for 15 min with PBS and fixed in 4% paraformaldehyde, followed by two additional washes in PBS. Slides were then mounted with DAPI-containing mounting medium (Vector laboratories), cover slipped, sealed with nail polish, and analyzed under an Olympus IX81 (Olympus) fluorescence microscope with an FV1000 confocal laser scanning unit (Olympus). Immunohistochemistry Tissue sections were fixed in 4% paraformaldehyde and embedded in paraffin. After deparaffinization, antigen retrieval was carried out using the IHC-Tek Epitope Retrieval Steamer Set (IHC World, Ellicott, MD, USA). To quench endogenous peroxidase activity, samples were treated with 3% hydrogen peroxide for 10 min. The sections were then incubated overnight at 4 °C with an anti-ALDOA antibody (Proteintech, Rosemont, IL, USA), an anti-Ki67 antibody (Cell Signaling), or an anti-phospho-S6 antibody (Abclonal). Signal detection was performed using either the UltraVision LP Detection System (Thermo Fisher Scientific) or Horseradish peroxidase-linked secondary antibodies (Abcam), followed by visualization with 3,3′-diaminobenzidine (DAB). Nuclei were counterstained using hematoxylin solution from Dako (Agilent, Santa Clara, CA, USA). Scoring was performed by a trained pathologist, who classified the staining intensity as 0 (negative), 1 (low positive), or 3 (high positive), according to a validated and previously described protocol [19]. Data analysis Publicly available TCGA-LUAD transcriptomic and clinical data were downloaded from the Genomic Data Commons data portal. Differential gene expression and survival analyses were performed using Python (v3.8), with the packages pandas, lifelines, and matplotlib. Gene expression was normalized as transcripts per million, and visualized using customized Python scripts. Statistical analysis All data are expressed as the mean ± standard error of the mean (SEM) from at least three independent experiments. Statistical comparisons were performed using Student’s t-test in Prism software, with p-values < 0.05 considered significant. Results High expression of ALDOA is associated with poor prognosis for patients with KRAS-mutant lung adenocarcinoma To assess the clinical relevance of ALDOA expression in the context of KRAS mutation, we analyzed The Cancer Genome Atlas (TCGA)-LUAD patient data by stratifying patients according to ALDOA mRNA levels and KRAS mutation status. Patients were categorized into ALDOA-elevated (top 25%) and ALDOA not-elevated (bottom 75%) groups, and stratified by KRAS mutation status (i.e., mutant or wild-type; Fig. 1A). While ALDOA levels did not differ significantly between KRAS-mutant and wild-type tumors, both groups showed higher expression of ALDOA than normal tissue, indicating general upregulation in lung adenocarcinoma (Fig. 1B). Kaplan–Meier survival analysis revealed that overall survival of patients with ALDOA-elevated tumors was significantly worse than that of patients with lower ALDOA-expressing tumors (Fig. 1C). When stratified by KRAS mutation status, this association was more pronounced in patients with KRAS mutation (Fig. 1D, E), although it remained statistically significant but less marked in the KRAS-wild-type subgroup (Fig. 1D, F). These findings suggest that although expression of ALDOA is not dependent on KRAS mutation status, its prognostic impact may be more pronounced in KRAS-mutated tumors. To validate these clinical correlations in vitro, we examined lung cancer cell lines categorized by KRAS mutation status and endogenous expression of ALDOA (Fig. 1G). KRAS-mutant cells (A549 and H358) exhibited greater internalization of Tetramethylrhodamine (TMR)-dextran, a marker of macropinocytosis, than KRAS-wild-type cells (i.e., H1437 and H522; Fig. 1H, I). To further evaluate lysosomal proteolytic activity following macropinocytosis, we assessed Dye-quenched (DQ)-BSA fluorescence, which increases upon lysosomal degradation of internalized proteins, and was confirmed to be lysosome-dependent by its marked reduction upon treatment with bafilomycin A1 (Figure S1). Among the tested cell lines, A549 cells with both KRAS mutation and high expression of ALDOA displayed the highest DQ-BSA fluorescence (Fig. 1H, J). By contrast, H358 cells, despite harboring a KRAS mutation, emitted a significantly weaker DQ-BSA signal than A549 cells, indicating that the efficiency of lysosomal degradation is determined by the level of ALDOA expression rather than by KRAS mutation status (Fig. 1H, J). Although TMR-dextran uptake was reduced in KRAS wild-type cells, a similar trend was observed in H1437 cells with relatively higher expression of ALDOA expression, which exhibited higher DQ-BSA fluorescence than H522 cells with relatively lower expression of ALDOA. Collectively, these findings suggest that while KRAS mutations enhance macropinocytosis in LUAD cells, ALDOA is a critical regulator of the lysosomal processing of macropinocytosed proteins, supporting its role in degradation after macropinocytotic acquisition of nutrients by KRAS-driven tumor cells. Expression of ALDOA correlates with a poor prognosis and enhanced macropinocytosis in LUAD. A Scatter plot illustrating the distribution of Aldolase A (ALDOA) mRNA expression in LUAD patients (N = 499). Patients were ranked according to ALDOA expression, and categorized into ALDOA-elevated (top 25%) and ALDOA non-elevated (bottom 75%) groups. KRAS mutation status is indicated by color (red: mutant, black: wild-type). B Expression of ALDOA mRNA in normal lung tissue, KRASWT LUAD, and KRASMut LUAD (N = 499) (C) Kaplan–Meier analysis illustrating the association between ALDOA mRNA expression and the prognosis of LUAD patients (N = 499). D Kaplan–Meier analysis illustrating the association between ALDOA mRNA expression and the prognosis of LUAD patients stratified by KRAS mutation status (N = 499). E Kaplan–Meier analysis illustrating the association between ALDOA mRNA expression and the prognosis of LUAD patients with KRAS mutation (N = 72). F Kaplan–Meier analysis illustrating the association between ALDOA mRNA expression and the prognosis of LUAD patients with KRAS.WT (N = 427). G ALDOA protein levels in A549, H358, H1437, and H522 cells. H Representative images of TMR-Dextran (red, upper panel) and DQ-BSA (green, lower panel) in A549, H358, H1437, and H522 cells. I, J Quantification of TMR-Dextran foci (I) and DQ-BSA fluorescence intensity (J) in the cells shown in H. All experimental data were verified in at least three independent experiments. Scale bar, 10 μm. Data are presented as the mean ± SEM. ns., not significant, **p < 0.01, and ***p < 0.001 ALDOA promotes lysosomal degradation of extracellular proteins independent of its glycolytic function To investigate the functional role of ALDOA during lysosomal processing following macropinocytosis, we used siRNA to silence ALDOA in A549 cells with high endogenous expression (Fig. 2A). Knocking down ALDOA did not alter TMR-dextran uptake significantly, suggesting that macropinocytosis was intact. However, ALDOA silencing led to a marked decrease in DQ-BSA fluorescence and accumulation of FITC-BSA protein, suggesting impaired lysosomal degradation of internalized proteins (Fig. 2B, S2A). Conversely, ectopic expression of ALDOA in H358 and H522 cells, both of which exhibit low expression of endogenous ALDOA, led to significant enhancement of DQ-BSA fluorescence and a reduction in FITC-BSA protein levels without affecting uptake of TMR-dextran (Fig. 2C–F and S2B, C), reinforcing the notion that ALDOA is dispensable for macropinocytic uptake, but essential for subsequent proteolytic processing. To determine whether this effect is dependent on the glycolytic function of ALDOA, we silenced phosphofructokinase, muscle type (PFKM), the upstream enzyme responsible for generating fructose-1,6-bisphosphate (F1,6BP), a known ALDOA substrate (Fig. 2G). Notably, PFKM knockdown did not affect DQ-BSA fluorescence (Fig. 2H). Furthermore, catalytically-inactive ALDOA mutants restored DQ-BSA fluorescence to levels comparable with that in wild-type ALDOA (Fig. 2I, J), indicating that ALDOA’s role in lysosomal degradation is independent of its enzymatic activity in glycolysis. Together, these results demonstrate that ALDOA enhances lysosomal degradation of extracellular proteins internalized via macropinocytosis through a glycolysis-independent mechanism, thereby highlighting its non-canonical role in alleviating nutrient stress via breakdown of alternatively acquired extracellular nutrients. ALDOA promotes lysosomal degradation of extracellular proteins independently of its glycolytic activity. A Effect of Aldolase A (ALDOA)-targeting siRNA on protein levels of ALDOA in A549 cells. B (upper) Representative images of TMR-Dextran (red) and DQ-BSA (green), and (lower) quantification of TMR-Dextran foci and DQ-BSA fluorescence intensity in ALDOA knock-downed A549 cells. C Effect of ALDOA overexpression on protein levels of ALDOA and FLAG-ALDOA in H358 cells. D Representative images (upper panel) and quantification (lower panel) of TMR-dextran in ALDOA-overexpressing H358 and H522 cells. E Effect of ALDOA overexpression on protein levels of ALDOA and FLAG-ALDOA in H522 cells. F Representative images (upper panel) and quantification (lower panel) of DQ-BSA in ALDOA-overexpressing H358 and H522 cells. G Effect of phosphofructokinase, muscle type (PFKM)-targeting siRNA on mRNA encoding PFKM in A549 cells. H Representative images (left panel) and quantification (right panel) of DQ-BSA in PFKM knockdown A549 cells. I Effect of ALDOAuntranslated region (UTR)-targeting siRNA or ALDOAMut overexpression on protein levels. J Representative images (left panel) and quantification (right panel) of DQ-BSA in ALDOAMut-overexpressing A549 cells transfected with ALDOA.UTR-targeting siRNA. All experimental data were verified in at least three independent experiments. Scale bar, 10 μm. Data are presented as the mean ± SEM. ns., not significant, **p < 0.01, and ***p < 0.001 ALDOA associates with the V-ATPase complex and regulates lysosomal acidification The vacuolar-type H⁺-ATPase (V-ATPase) complex is essential for maintaining the acidic environment of lysosomes, which is critical for proteolytic degradation [20, 21]. Based on prior evidence showing an interaction between ALDOA and subunits of the V1 domain of V-ATPase [12], we investigated whether ALDOA contributes to lysosomal acidification through this interaction. Immunofluorescence analysis of A549 cells revealed co-localization of ALDOA with lysosomes, as indicated by the overlap of ALDOA and Lysotracker signals (Fig. 3A). Consistent with these findings, immunoblotting of lysosome-enriched fractions confirmed colocalization of ALDOA with the lysosomal marker LAMP1 (Fig. 3B), demonstrating that ALDOA is localized to lysosomes. Immunoprecipitation assays confirmed that ALDOA associates with both ATPase H+ transporting V0 subunit a2 (ATP6V0A2) and ATPase H+ transporting V1 subunit b2 (ATP6V1B2), key subunits of the V₀ and V₁ domains of the V-ATPase complex, respectively (Fig. 3C). Notably, silencing ALDOA disrupted co-localization of ATP6V1B2 with the lysosomal membrane marker Lysosome-associated membrane protein 1 (LAMP1) (Fig. 3D), suggesting that ALDOA promotes assembly of V-ATPase at the lysosomal membrane. To assess the functional consequences of this interaction, we measured lysosomal mass and acidity using LysoPrime Green and pHLys Red, respectively. In A549 cells, knocking down ALDOA did not alter LysoPrime Green staining; however, it reduced pHLys Red fluorescence significantly, indicating impaired lysosomal acidification (Fig. 3F). Conversely, enforced expression of ALDOA in H358 and H522 cells, both of which express low levels of endogenous ALDOA, led to increased pHLys Red fluorescence without affecting lysosomal mass, a finding consistent with increased acidification capacity (Fig. 3G, H). Because the position of lysosomes within a cell can affect their functionality and acidity [22, 23], we analyzed lysosome distribution and found that knockdown of ALDOA did not alter lysosome positioning (Fig. 3I). Collectively, these findings demonstrate that ALDOA promotes assembly of the V-ATPase complex at the lysosomal membrane, thereby facilitating lysosomal acidification essential for proteolytic activity. ALDOA interacts with V-ATPase to increase lysosomal acidification. A Representative immunofluorescence images of Lysosome (red) and Aldolase A (ALDOA) (green) in A549 cells. B Immunoblot analysis to detect ALDOA in lysosome-enriched fractions derived from A549 cells. Lysosomal Associated Membrane Protein 1 (LAMP1), a lysosome marker; Cytochrome c oxidase subunit 4 (COX4), a mitochondria marker; Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH), a cytosol marker; Calnexin (CANX), an ER marker; and Golgi matrix protein 130 kDa (GM130), a Golgi marker. C Immunoprecipitation of endogenous ALDOA, followed by immunoblotting to detect ALDOA, ATPase H+ transporting V0 subunit a2 (ATP6V0A2), and ATPase H.+ transporting V1 subunit b2 (ATP6V1B2) in A549 cells. D–E Representative immunofluorescence images of Lysosome (red) and ATP6V1B2 (green) (D), and quantitative analysis of co-localization of lysosome-associated membrane protein 1 (LAMP1) and ATP6V1B2 proteins using Mander’s coefficient (right panel) in ALDOA-knockdown A549 cells (E). F Representative images of lysosomal pH analysis (left panel), and quantification of LysoPrime Green foci and pHLys Red fluorescence intensity (right panel) in ALDOA-knockdown A549 cells. G, H Representative images of lysosomal pH analysis (left panel), and quantification of LysoPrime Green foci and pHLys Red fluorescence intensity (right panel), in ALDOA-overexpressing H358 (G) and H522 (H) cells. I Representative immunofluorescence images of lysosomes (LAMP1, red) and nuclei (DAPI, blue) in ALDOA-knockdown A549 cells. Dashed concentric lines indicate five evenly divided shells drawn from the cell periphery toward the nucleus. Shells #1–3 represent the peripheral region, and shells #4–5 the perinuclear region. (left panel). Quantification of lysosomal distribution shows the fraction of the total lysosomal area localized to peripheral versus perinuclear regions under each condition (right panel). All experimental data were verified in at least three independent experiments. Scale bar, 10 μm. Data are presented as the mean ± SEM. ns., not significant, *p < 0.05, **p < 0.01, and ***p < 0.001 ALDOA is required for macropinocytosis-mediated activation of mTORC1 and cell growth under conditions of nutrient deprivation To elucidate the functional role of ALDOA in supporting cell proliferation under conditions of amino acid deprivation, we cultured cells in leucine-free medium and assessed lysosomal localization, mTORC1 signaling, and growth responses. Immunofluorescence analysis of A549 cells revealed that co-localization of ALDOA and LAMP1 increased upon withdrawal of leucine, indicating increased recruitment of ALDOA to lysosomes under conditions of amino acid starvation (Figure S3). In A549 cells, leucine deprivation reduced phosphorylation of S6K (p-S6K), ULK1 (p-ULK1), and 4EBP1 (p-4EBP1), all key downstream effectors of mTORC1, markedly (Fig. 4A). Supplementation with bovine serum albumin (BSA) partially restored p-S6K, p-ULK1, and p-4EBP1 levels, a finding consistent with prior reports that extracellular proteins internalized via macropinocytosis can serve as alternative nutrient sources for mTORC1 activation [24]. However, this rescue effect was abolished in ALDOA-knockdown cells, indicating a critical role for ALDOA in restoring amino acid-driven mTORC1 activity in amino acid-deprived cells (Fig. 4A). In line with these findings, BSA supplementation increased cell proliferation during leucine starvation, but this effect was similarly abrogated by ALDOA depletion, while cell viability remained unaffected (Fig. 4B, C), further support the requirement of ALDOA for processing of scavenged nutrients via macropinocytosis. Next, we asked whether overexpression of ALDOA augments protein-derived nutrient utilization by cells with low levels of endogenous ALDOA. In both H358 and H522 cells, forced expression of ALDOA increased BSA-mediated mTORC1 reactivation and promoted proliferation, again without impacting cell viability under leucine-deficient conditions (Fig. 4D–I). Collectively, these results demonstrate that ALDOA facilitates lysosomal processing of extracellular proteins, thereby enabling mTORC1 reactivation and sustaining cell growth in nutrient-limited environments. ALDOA supports activation of mTORC1 and proliferation of LUAD cells during amino acid starvation. A-C Effects of bovine serum albumin (BSA) supplementation on expression of phospho-S6K, phospho-ULK1, and on phospho-4EBP1 expression (A), cell proliferation (B), and viability (C) of leucine-deprived A549 cells transfected with Aldolase A (ALDOA) siRNA. D–F Effects of BSA supplementation on expression of phospho-S6K, phospho-ULK1, and phospho-4EBP1 (D), and on proliferation (E), and viability (F) of leucine-deprived H358 cells transfected with an ALDOA expression plasmid. G–I Effect of BSA supplementation on phospho-S6K, phospho-ULK1, and phospho-4EBP1 expression (G), and on proliferation (H), and viability (I) of leucine-deprived H522 cells transfected with an ALDOA expression plasmid. All experimental data were verified in at least three independent experiments. Data are presented as the mean ± SEM. ns., not significant, *p < 0.05, **p < 0.01, and ***p < 0.001 ALDOA supports macropinocytosis and mTORC1 signaling under anchorage-independent conditions To more accurately mimic the metabolic and adhesive constraints faced by tumor cells in vivo, we cultured A549 cells under conventional adherent (2D) and suspension-based poly-HEMA–coated (3D) conditions. Although only a small fraction of tumor cells detach, extravasate, and circulate through the blood or lymphatic system in vivo, suspension culture provides an experimental approach that recapitulates the anchorage-independent state required for metastatic dissemination [25, 26]. Compared with those grown in 2D culture, 3D-grown cells exhibited increased uptake of TMR-dextran and elevated DQ-BSA fluorescence, indicating increased macropinocytosis and lysosomal protein degradation (Fig. 5A). Notably, knockdown of ALDOA under 3D conditions selectively reduced DQ-BSA fluorescence without altering TMR-dextran uptake (Fig. 5A), pointing to specific impairment of lysosomal proteolysis rather than cargo internalization. Given that amino acid transport via membrane transporters is often compromised under anchorage-independent conditions, we next assessed expression of key amino acid transporters [27]. Western blot analysis revealed that key amino acid transporters, including SLC1A5, SLC38A1, SLC38A2, SLC7A5, and SLC3A2, were downregulated under 3D culture conditions (Fig. 5B), suggesting a shift toward alternative nutrient acquisition mechanisms such as macropinocytosis. Consistent with this, both mTORC1 activity and cell proliferation fell under 3D conditions, but were partially restored by BSA supplementation. These effects were abolished either by ALDOA silencing or pharmacological inhibition of macropinocytosis using 5-(N-Ethyl-N-isopropyl)amiloride (EIPA) (Fig. 5C, D), reinforcing the role of ALDOA in protein nutrient utilization. Interestingly, although total ALDOA protein levels remained stable between 2 and 3D cultures, immunofluorescence analysis revealed a significant increase in co-localization of ALDOA with the lysosomal marker LAMP1 under 3D conditions (Fig. 5E), suggesting that ALDOA is recruited dynamically to lysosomes in response to environmental stress. Taken together, these data indicate that ALDOA promotes lysosomal degradation of macropinocytosed proteins by suspended tumor cells, thereby supporting mTORC1 signaling and cell proliferation under nutrient- and adhesion-limited conditions. ALDOA promotes macropinocytic lysosomal degradation and mTORC1 activation under 3D culture conditions. A Effects of Aldolase A (ALDOA)-targeting siRNA on TMR-Dextran uptake and DQ-BSA fluorescence (left panel), and quantification (right panel) of TMR-Dextran foci and DQ-BSA fluorescence intensity, in A549 cells cultured under 2D or 3D conditions. B Protein levels of SLC1A5, SLC38A1, SLC38A2, SLC7A5, and SLC3A2 in A549 cells under 2D or 3D conditions. C Effects of bovine serum albumin (BSA) supplementation on proliferation of leucine-deprived A549 cells transfected with ALDOA-targeting siRNA under 3D conditions. D Effects of BSA supplementation on phospho-S6K, phospho-ULK1, and phospho-4EBP1 levels in leucine-deprived A549 cells transfected with ALDOA-targeting siRNA under 2D or 3D conditions. E Representative immunofluorescence images of Lysosome (red) and ALDOA (green) (left panel), and quantitative analysis of protein co-localization between lysosome-associated membrane protein 1 (LAMP1) and ALDOA using Mander’s coefficient (right panel), in 2D or 3D cultured A549 cells. All experimental data were verified in at least three independent experiments. Scale bar, 10 μm. Data are presented as the mean ± SEM. ns., not significant, *p < 0.05, **p < 0.01, and ***p < 0.001 Targeting ALDOA inhibits tumor growth Building upon our in vitro finding that ALDOA promotes lysosomal protein catabolism, we next evaluated its contribution to tumor growth in vivo. A549 cells stably expressing either control sgRNA (Ctrl) or ALDOA-targeting sgRNA (sgALDOA) were established, and subjected to immunoblotting to confirm efficient knockdown of ALDOA (Fig. 6A). To assess the functional impact of ALDOA knockdown, we compared proliferation under nutrient-replete and nutrient-deprived conditions. We found that proliferation of sgALDOA and control cells was similar in the presence of leucine, but only control cells showed BSA-dependent growth rescue during leucine starvation. This effect was abolished in sgALDOA cells (Fig. 6B), confirming that ALDOA is required for processing exogenous protein nutrients. Tumor growth analysis revealed that the volume of both sgALDOA tumors and EIPA-treated Ctrl tumors was significantly smaller than that of Ctrl tumors (Fig. 6C, D). Notably, combining ALDOA loss with EIPA treatment did not confer additional growth suppression, suggesting that ALDOA and macropinocytosis operate within a shared pathway to support tumor growth. Immunofluorescence staining of tumor sections revealed robust co-localization of ALDOA with LAMP1 in Ctrl tumors, supporting a lysosome-associated function of ALDOA in vivo (Fig. 6E). Furthermore, DQ-BSA fluorescence in sgALDOA and EIPA-treated tumors was markedly lower than that in Ctrl tumors, reflecting impaired degradation of extracellular proteins (Fig. 6F). Consistent with impaired nutrient processing, ALDOA-deficient and macropinocytosis-inhibited tumors exhibited significantly lower levels of Ki67 and phospho-S6, consistent with decreased proliferative capacity and suppressed mTORC1 activity (Fig. 6G). Immunofluorescence analysis further confirmed that ALDOA was significantly reduced in α-SMA–negative tumor cells in sgALDOA tumors, demonstrating effective depletion of ALDOA in cancer cells (Fig. 6H). Collectively, these findings highlight ALDOA as a key mediator of macropinocytosis-dependent nutrient utilization in vivo, suggesting that its inhibition may offer therapeutic benefit, particularly in tumors, such as KRAS-driven cancers, that rely on macropinocytic pathways. Targeting ALDOA impairs lysosomal proteolysis and tumor growth in vivo. A Immunoblot analysis confirming the effect of Aldolase A (ALDOA)-targeting sgRNA on protein levels of ALDOA in A549 cells. B Effects of bovine serum albumin (BSA) supplementation on proliferation of sgALDOA cells under leucine-replete and leucine-deprived conditions. C, D Representative gross images (C) and growth curves (D) of xenografted tumors derived from A549 control or sgALDOA cells, treated with or without the macropinocytosis inhibitor 5-(N-Ethyl-N-isopropyl)amiloride (EIPA) (N = 6 per group). E Representative immunofluorescence images of Lysosome (red) and ALDOA (green) in tumor tissues from xenografted A549 models. Arrows indicate colocalized puncta. F Representative images of DQ-BSA fluorescence (left panel) and quantification of DQ-BSA fluorescence intensity (right panel) in tumor tissue formed after subcutaneous injection of Ctrl or sgALDOA A549 cells, with or without EIPA treatment. G Representative histological (H&E) and immunohistochemical images of Ki67 and p-S6 staining (left panel), and quantification of Ki67 and p-S6 expression scores (right panel), in xenograft tumor sections. H Representative immunofluorescence images of ALDOA (green) and α-smooth muscle actin (α-SMA, red) in xenograft tumor sections (left panel), and quantification of ALDOA fluorescence in α-SMA–negative cells (right panel). All experimental data were verified in at least six independent experiments. Scale bar, 10 μm. Data are presented as the mean ± SEM. ns., not significant, **p < 0.01, and ***p < 0.001 Discussion Our study revealed a previously uncharacterized, non-enzymatic role of ALDOA in promoting lysosomal protein degradation under nutrient-limiting conditions. We show that ALDOA interacts physically with V-ATPase subunits, thereby facilitating lysosomal acidification, a function distinct from ALDOA’s canonical role in glycolysis. Prior studies show that ALDOA regulates assembly of V-ATPase and couples glucose availability to proton pump function, thereby integrating energy metabolism with pH homeostasis [11]. A more recent study shows that depleting ALDOA activates the V-ATPase–AMPK axis, revealing the significance of ALDOA for tumor metabolic adaptation and growth regulation [28]. Our findings extend these observations by demonstrating that ALDOA supports V-ATPase assembly to facilitate lysosomal acidification and promote macropinocytosis-dependent nutrient acquisition in KRAS-mutant lung adenocarcinoma cells, thereby sustaining mTORC1 signaling and tumor growth. Previous studies show that cancer cells can bypass de novo biosynthetic pathways by replenishing essential amino acids through macropinocytosis, thereby acquiring resistance to therapies targeting nucleotide and lipid synthesis, particularly under conditions of metabolic stress [29, 30]. This process is upregulated markedly in KRAS-mutant tumors, and serves as a critical route for amino acid acquisition [3]. This dependency highlights the role of lysosomal proteolysis in allowing tumor cells to utilize extracellular proteins as a source of essential metabolites. Despite growing insight into macropinocytosis within the context of tumor nutrient adaptation, the downstream lysosomal mechanisms responsible for processing internalized proteins remain poorly understood. Here, we identify ALDOA as a critical mediator of this pathway via promotion of lysosomal acidification and linking extracellular protein uptake to efficient intracellular degradation, thereby providing metabolic flexibility under nutrient-limited conditions. Functional analyses revealed that KRAS-mutant, ALDOA-high cells coordinately upregulated macropinocytosis and lysosomal proteolysis. Expression of ALDOA directly correlated with proteolytic efficiency across KRAS-mutant lines, as evidenced by reduced DQ-BSA fluorescence in ALDOA-low cells. In vivo, depletion of ALDOA recapitulated the tumor-suppressive effects of macropinocytosis inhibition, with non-additive effects indicating that ALDOA-mediated lysosomal proteolysis contributes to macropinocytosis-dependent nutrient acquisition. The clinical relevance of these findings is further supported by our analysis of TCGA-LUAD patient data, showing that high expression of ALDOA is associated with a significantly poorer prognosis, especially for patients with KRAS-mutant lung adenocarcinoma. This association also extended to KRAS wild-type tumors, suggesting that the pathological role of ALDOA is not restricted to a single oncogenic context. The consistent implication of ALDOA involvement across different KRAS contexts highlights its central role in metabolic adaptation and underscores its potential as both a broad-spectrum prognostic biomarker and a therapeutically actionable target in nutrient-scavenging cancers. Increasingly, ALDOA has been recognized as having a range of non-glycolytic, "moonlighting" functions in cancer [9, 10]. For instance, ALDOA interacts with key DNA repair kinases such as the DNA-dependent protein kinase catalytic subunit and ataxia telangiectasia mutated, thereby suppressing DNA damage responses and promoting tumor cell survival [31]. It also modulates mRNA translation in hepatocellular carcinoma by binding IGF2BP1 [10], and regulates autophagy and cytoskeletal dynamics through non-enzymatic interactions with regulatory proteins [32, 33]. These findings highlight the broad regulatory influence of ALDOA on gene expression, cellular dynamics, and stress responses, thereby reinforcing its pivotal role in maintaining cellular homeostasis and promoting tumor progression. Building on this, our study identifies a novel non-enzymatic function of ALDOA in promoting lysosomal protein degradation by facilitating V-ATPase-mediated acidification. While prior studies hinted at interactions between ALDOA and V-ATPase subunits [11], the functional consequences of this interaction for lysosomal activity and, specifically, for the processing of macropinocytosed cargo remained unknown. In this study, we demonstrate that this activity is independent of the glycolytic function of ALDOA and serves as a key mediator of lysosomal proteolysis, nutrient acquisition, mTORC1 signaling, and tumor growth, particularly under nutrient-limited and anchorage-independent conditions, with especially pronounced relevance in the context of KRAS-mutant lung adenocarcinoma. Despite the mechanistic insights offered in this study, some limitations remain. Although extracellular proteins supplied essential metabolites in vitro, nutrient-rescue experiments were not performed in vivo; therefore, it remains unresolved whether protein-derived nutrients can compensate for ALDOA loss within the physiological tumor microenvironment. Additionally, while ALDOA interacts with V-ATPase subunits to promote lysosomal acidification, the structural determinants and assembly dynamics underlying this interaction remain unclear. Finally, because this study focused primarily on macropinocytic protein degradation, the contribution of alternative nutrient-scavenging pathways was not assessed. Future studies are necessary to determine the mechanisms underlying the coordination of multiple metabolic pathways by ALDOA to support metabolic adaptation in tumors. In conclusion, by establishing a mechanistic link between extracellular nutrient uptake via macropinocytosis and intracellular lysosomal degradation through a novel non-enzymatic function of ALDOA, our study deepens the understanding of tumor metabolic flexibility. These insights suggest that targeting ALDOA could effectively disrupt a critical nutrient supply route, as well as adaptive mTORC1 signaling, in nutrient-stressed cancers, presenting a compelling strategy for future therapeutic development. Supplementary Information Supplementary Material 1 Supplementary Material 2. Supplementary figure 1. Bafilomycin A1 inhibits lysosomal degradation of DQ-BSA in A549 cells. Representative imagesand quantificationof DQ-BSA in bafilomycin A1-treated A549 cells. All experimental data were verified in at least three independent experiments. Scale bar, 10 μm. Data are presented as the mean ± SEM. **p < 0.01. Supplementary Material 3. Supplementary figure 2. Aldolase Asupports lysosomal degradation of extracellular proteins.Effect of ALDOA knockdown on FITC-BSA degradation in A549 cells.Effect of ALDOA overexpression on FITC-BSA degradation in H358and H522cells Supplementary Material 4. Supplementary figure 3. Aldolase Ashows enhanced lysosomal localization under leucine deprivation in A549 cells. Representative immunofluorescence images of Lysosomeand ALDOA, and quantitative analysis of co-localization of LAMP1 and ALDOA proteins using Mander’s coefficient, under leucine-deprived A549 cells. All experimental data were verified in at least three independent experiments. Scale bar, 10 μm. Data are presented as the mean ± SEM. **p < 0.01. Acknowledgements Not applicable. Abbreviations Aldolase A α-Smooth muscle actin ATPase H+ transporting V0 subunit a2 ATPase H+ transporting V1 subunit b2 Bovine serum albumin Calnexin Cytochrome c oxidase subunit 4 3,3′-Diaminobenzidine Dye-quenched 5-(N-Ethyl-N-isopropyl) amiloride Glyceraldehyde 3-Phosphate Dehydrogenase Golgi matrix protein 130 kDa Hanks' Balanced Salt Solution Lysosome-associated membrane protein 1 Optimal Cutting Temperature Phosphate-buffered saline Phosphofructokinase Muscle type Polyvinylidene difluoride The Cancer Genome Atlas Tetramethylrhodamine Unc-51-like kinase 1 Untranslated region Vacuolar-type H⁺-ATPase Eukaryotic translation initiation factor 4E-binding protein 1 Authors’ contributions D.K. designed the research, performed the experiments, and wrote the manuscript. S.J. and S.L performed the experiments. J.J. interpreted the data. J.W.Y. and J.L. executed and interpreted the TCGA data. J-K.B. conceived the study, designed the research, and interpreted the data. Y-K.C. designed the research, interpreted the data, and wrote the manuscript. K-G.P. designed the experiments, analyzed and interpreted the data, edited the manuscript, and supervised the project. Funding This work was supported by National Research Foundation of Korea through grants, funded by the Ministry of Science and ICT (RS-2021-NR059744, RS-2025–00522567, RS-2020-NR049556), and by the Basic Science Research Program through the NRF funded by the Ministry of Education (RS-2025–25397788). Data availability The data supporting the conclusions of this article have been provided in this article. In addition, all data from this study can be obtained from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate Animals were housed in the Laboratory Animal Research Center of Kyungpook National University and maintained according to the guidelines of its Institutional Animal Care and Use Committee, who approved all animal procedures. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Jun-Kyu Byun, Email: jkbyun@knu.ac.kr. Yeon-Kyung Choi, Email: ykchoi@knu.ac.kr. Keun-Gyu Park, Email: kpark@knu.ac.kr. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2. Supplementary figure 1. Bafilomycin A1 inhibits lysosomal degradation of DQ-BSA in A549 cells. Representative imagesand quantificationof DQ-BSA in bafilomycin A1-treated A549 cells. All experimental data were verified in at least three independent experiments. Scale bar, 10 μm. Data are presented as the mean ± SEM. **p < 0.01. Supplementary Material 3. Supplementary figure 2. Aldolase Asupports lysosomal degradation of extracellular proteins.Effect of ALDOA knockdown on FITC-BSA degradation in A549 cells.Effect of ALDOA overexpression on FITC-BSA degradation in H358and H522cells Supplementary Material 4. Supplementary figure 3. Aldolase Ashows enhanced lysosomal localization under leucine deprivation in A549 cells. Representative immunofluorescence images of Lysosomeand ALDOA, and quantitative analysis of co-localization of LAMP1 and ALDOA proteins using Mander’s coefficient, under leucine-deprived A549 cells. All experimental data were verified in at least three independent experiments. Scale bar, 10 μm. Data are presented as the mean ± SEM. **p < 0.01. Data Availability Statement The data supporting the conclusions of this article have been provided in this article. In addition, all data from this study can be obtained from the corresponding author upon reasonable request.